Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.

Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections cover key regulatory pathways that mediate acute and chronic inflammation and disease onset. Further chapters are devoted to advanced anti-inflammatory pharmaceuticals, including chemical moieties, pharmacophores, APIs, natural products, herbal therapies, molecular nanomedicine and advanced drug delivery vectors. Systematically planned chapters and illustrations enable potential readers to gain essential insights on the most recent advancements in the field. Arranged with systematic chapters covering a broad range of inflammatory diseases, discussions on past, current and future therapeutics and advanced anti-inflammatory pharmaceuticals, this book will be useful to a wide range of researchers, especially medicinal chemists, drug design experts, and biological and translational researchers working in the field of inflammation.

This two volume Second Edition describes the anatomical, physiological, pharmaceutical, and technological aspects of delivery routes, found in areas like:

• Oral
• Ocular
• Dermal and transdermal
• Vaginal
• Colonic
• Oral mucosal
• Nasal
• Pulmonary

Providing insight and critical assessment of the many available and emerging modified release drug delivery systems for their current and future value, topics include:

• Intellectual property rights and regulatory issues and challenges
• osmotic systems and Qtrol. Qdis. Matrix Systems
• thiolated polymers for CR, Oradur. IDD technology, and chronotherapy technology
• Oral-lyn (RapidMist Technology)
• Dentipatch drug delivery system
• ORAVESCENT: a novel technology for the transmucosal delivery of drugs
• Egalet and COLAL technologies

'A splendid read. Via interviews with several Secretaries of State for Education and a supporting analytical commentary, Education Policy provides a fascinating insight and historical appraisal of English policy rationale' -Dr David Kitchener, Reader in Education, University of Bolton 'This book should be compulsory reading, not only for people interested in the history of education policy but also for policy makers, to remind them of what has gone before' -Dr Andrew Townsend, University of Nottingham From Butler to Balls and beyond, this essential book illuminates educational issues in England and Wales since WWII, drawing on extensive documentary evidence. Inside you will find in-depth interviews with former Secretaries of State for Education and other key decision-makers, including: - Ed Balls - David Blunkett - Michael Gove - Alan Johnson - Ruth Kelly The interviews cover the historical context of their period of office and the lasting legacy of their policies. This is a must-read for Masters-level students on Education courses and PGCE programmes, and will be valuable to undergraduates studying modern history and social policy. Ian Abbott is Director of the Warwick Institute of Education. Mike Rathbone was previously Director of Continuing Professional Development in the Institute of Education. Phil Whitehead is the course leader for the secondary PGCE (Teach First). All are at the University of Warwick.

Because of the slow and costly process of developing new blockbuster drugs, pharmaceutical scientists are increasingly charged with reformulating existing drugs in order to expand a company's market opportunity and to sustain company growth. This presents an opportunity for formulation scientists to innovate and develop novel drug delivery systems to extend the commercial life of existing drugs. Divided into two volumes, this "Second Edition" describes the anatomical, physiological, pharmaceutical, and technological aspects of oral, colonic and rectal, ocular, oral mucosal, dermal and transdermal, nasal, vaginal, and pulmonary delivery routes, providing insight and critical assessment of the many available and emerging modified release drug delivery systems for their current and future value.

NTI/Sales Copy